IM96 CAR-T cells / Beijing Imunopharm - LARVOL DELTA

Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer. (ASCO 2024) - P1 | "Pts were pre-treated with fludarabine and cyclophosphamide, and received a single infusion of IM96 at the dose of 3×10 8 (DL1), 6×10 8 (DL2), 12×10 8 (DL3), or 20×10 8 (DL4) CAR-T cells... This study demonstrated that IM96 has durable efficacy with acceptable safety profile in pMMR mCRC pts, in particularly, showing high therapeutic potential in liver metastasis pts."

Clinical • IO biomarker • Metastases • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Mucositis • Oncology • Solid Tumor • Stomatitis • BRAF • CEACAM5 • GUCY2C • IL6 • KRAS • NRAS

Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.

IO biomarker • New P1 trial • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CA 19-9 • GUCY2C

Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.

CAR T-Cell Therapy • Metastases • New P1 trial • Colorectal Cancer • Oncology • Solid Tumor

Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer (ESMO 2023) - P1 | "Pts were pre-treated with fludarabine and cyclophosphamide, and received a single infusion of IM96 at the dose of 3×108 (DL1), 6×108 (DL2), 12×108 (DL3), or 20×108 (DL4) CAR-T cells...The clinical response is correlated with tumor GCC expression, infusion dose, and CAR-T expansion level. This study is ongoing, and dose extensive investigation will also be performed."

Clinical • IO biomarker • Metastases • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • IL6

Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms (clinicaltrials.gov) - P1 | N=19 | Recruiting | Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.

CAR T-Cell Therapy • New P1 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor